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1.
Introduction 1 PER is a recently introduced AED which acts as a non-competitive antagonist at AMPA receptors in the brain, so reducing neuronal excitability. [1] PER was licensed as add-on treatment in focal epilepsy following results from three randomised controlled trials in people with pharmacoresistant epilepsy. [2] [3] [4] Regulatory trials establish whether an AED is effective, but do not inform about its use in "reallife" population with epilepsy, many of whom might not meet the inclusion criteria for these trials for a number of reasons. We have evaluated the use of newly introduced AEDs over the past 20 years. [5] [6] [7] [8] [9] [10] Here, we present a similar observation on the use of PER. 1 Abbreviations: AED -antiepileptic drug IQR -interquartile range PER -perampanel SD -standard deviation SUDEP -sudden unexplained death in epilepsy 2.
Patients and Methods
Adults 17 years and older with epilepsy who received their first prescription for PER at the epilepsy specialist clinics at National Hospital for Neurology and Neurosurgery (Queen Square and Chalfont sites) between 1 October 2012 and 31 March 2015 were identified using the hospital's central pharmacy database and the departmental database. People started on PER elsewhere were excluded to avoid referral bias. Data regarding epilepsy syndrome, seizure types, age at onset of epilepsy, psychiatric comorbidity (if listed in records or inferred by use of antidepressant or antipsychotic medications), presence of learning disability, and use of current and previous AEDs, date of starting and stopping (where applicable) PER, maximum attained dose and maintenance dose were extracted from records. All started PER as add-on treatment.
The starting dose was 2 mg per day and was typically increased every two to four weeks by 2 mg as tolerated. At our center, people with epilepsy are typically seen every six months, though they are encouraged to make phone contact in between if needed. All encounters with epilepsy care providers were analyzed to assess effect on seizure frequency and severity, adverse effects, and reasons to discontinue PER where applicable. Effect on seizures was categorized as seizure freedom for >5 times the average interval in between seizures during the previous year, a reduction in seizures by 50% or more, any other marked improvement in the assessment of either the individual or the physician, or worsening of seizures. Examples of marked improvement were cessation of convulsions, significant shortening of seizure or postictal confusion duration or reduction in seizure related falls or injuries. These categories were mutually exclusive except for periods of temporary seizure freedom (i. e. a person who reported initial seizure freedom of six months, followed by >50% reduction in seizure freedom for 12 months, appeared in both categories). We only considered beneficial effects lasting six months or longer in the analysis to avoid the regression to mean phenomenon. [11] Seizure aggravation was noted if there was a significant increase in seizure frequency or seizure related morbidity. People were followed until they discontinued PER; data were censored on 10 September 2016 for those continuing on PER.
Current AED use was assessed on the day of starting PER; i. e. changes in AEDs other than PER were not captured. Three people underwent temporal lobe resections after starting PER. Improvement following surgery was not attributed to PER. This exercise was approved as an audit, and no ethics approval was necessary. Those who reported side effects attained lower maximum doses than those who did not.
3.2.
Benefits of perampanel 19 people (5%) reported periods of seizure freedom lasting 6 months or more. This benefit was temporary for up to 19 (median 9) months in ten, and ongoing at last follow up for up to 38 (18) months in nine. A reduction in seizure frequency by >50% for 6 months or longer was seen in 76 (20%), temporary for up to 36 (17) than those who did not report this benefit (mean 10.1, median 10, range 2-21, p=0.003). There were no differences in the number of previously failed AEDs for the subgroups who reported seizure reduction by 50% or more for six months or longer, or those who reported "marked improvement" for six months or longer, versus those who did not. We then performed a stepwise multivariate backwards regression analysis including all parameters that had been found to have an association (positive or negative) with PER retention at a level of p<0.2 (table 5). Concomitant use of pregabalin and maximum attained dose remained positively associated with PER retention, as did periods of benefits as described above.
Worsening of seizures, presence of psychiatric or somatic side effects and concomitant use of zonisamide were negatively associated with PER retention at a significance of p<0.05. Table 4 and 5 about here There were no differences in the number of people who reported somatic or psychiatric side effects when comparing the subgroups who were on concomitant pregabalin or zonisamide when starting PER with those who were not on these AEDs. There were also no differences in the continuing or maximum dose attained in those on concomitant pregabalin or zonisamide versus those not on these AEDs. Retention rates at one, two and three years in this cohort were similar to those observed in our historical cohort of people on lacosamide at one (60% for PER vs 62% for lacosamide) and two years (48% vs 45%), and slightly better at three years (43% vs 35%). [9] While these two cohorts were similar in regards to their demographic characteristics, people in the PER cohort had failed one more AED (median) than those in the lacosamide cohort.
Figure,
Prior observational studies on PER use have reported 12 months retention rates of 46 -60.6% [16] [17] [18] [19] [20] , with broadly similar rates and types of side effects.
During enrolment, PER was licensed as add-on treatment for focal seizures only. The drug was used "off-label" in 17% of the cohort at the discretion of the prescribing physician. In June 2015, the indication for PER was expanded to add-on in primary generalized tonic clonic seizures.
There were no differences in PER retention or attained doses of PER for people age 60 years or older compared to those younger than 60 years, in line with the findings of a post-hoc analysis of people age 65 and above in the PER regulatory trials. [21] Adverse effects on mental health were reported by more than one third of people in line previous reports. [17] [19] We did not systematically collect data with regards to specific side effects that lead to discontinuation. Psychiatric side effects judged to be severe in this cohort were observed in three. The possibility of these side effects should be discussed with individuals and PER should be used cautiously in people with a history of aggressive behavior.
PER retention was positively affected by concomitant use of pregabalin and negatively by zonisamide. There were no differences in the presence of somatic or psychiatric adverse effects, and no differences in the doses attained in those who took PER with or without combination with pregabalin or zonisamide. No pharmacodynamic or pharmacokinetic interaction between pregabalin and PER or zonisamide and PER have been yet described. [1] [22] The observed effects of concomitant use of certain AEDs on PER retention might be a statistical artefact, the potential beneficial effect of pregabalin was the factor with the strongest modifiable effect in both univariate and multivariate Cox regression analysis. We therefore believe that this potential association deserves further investigation.
From a practical standpoint, our data suggest that a substantial minority of people with pharmacoresistant epilepsy experience some form of benefit from PER, despite having failed many AEDs. Further observations are warranted to determine whether PER might be more beneficial in people who have failed fewer AEDs. Adverse effects on mental health are the most relevant in clinical practice. These should be thoroughly discussed with individuals and actively explored after starting PER.
.
Limitations
There are a number of limitations: PER effects were not prospectively assessed but retrospectively collected and may thus be subject to recall and reporting bias. We relied on data that were not systematically captured during routine clinical encounters and documented in medical records only. The documented use of previous AEDs therefore may have underestimated the actual use, in particular in those who had apparently failed only few AEDs prior to PER. These effects were, however, judged to be small and thus unlikely to affect the analysis on retention. Seizure counts have been shown to be inaccurate [23] , and no systematic use of seizure diaries was ensured. Beneficial effects in few individuals may have been falsely attributed to PER in the presence of another intervention (e. g. further subsequent drug change in rare cases), though we did not attribute benefits that appeared after resective epilepsy surgery. 58% 
